Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patien...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of epidemiology Vol. 110; no. 2; p. 105
Main Authors Schonberger, L B, Bregman, D J, Sullivan-Bolyai, J Z, Keenlyside, R A, Ziegler, D W, Retailliau, H F, Eddins, D L, Bryan, J A
Format Journal Article
LanguageEnglish
Published United States 01.08.1979
Subjects
Adolescent
Adult
Age Factors
Aged
Continental Population Groups
Drug Industry
Female
Humans
Influenza Vaccines - adverse effects
Male
Middle Aged
Polyradiculoneuropathy - diagnosis
Polyradiculoneuropathy - epidemiology
Polyradiculoneuropathy - etiology
Sex Ratio
Time Factors
United States
United States
Online AccessGet more information

Cover

More Information
Summary:Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patients with onset of GBS from October 1, 1976, to January 31, 1977, from all 50 states, District of Columbia, and Puerto Rico. A total of 532 patients had recently received an A/New Jersey influenza vaccination prior to their onset of GBS (vaccinated cases), and 15 patients received a vaccination after their onset of GBS. Five hundred forty-three patients had not been recently vaccinated with A/New Jersey influenza vaccine and the vaccination status for 8 was unknown. Epidemiologic evidence indicated that many cases of GBS were related to vaccination. When compared to the unvaccinated population, the vaccinated population had a significantly elevated attack rate in every adult age group. The estimated attributable risk of vaccine-related GBS in the adult population was just under one case per 100,000 vaccinations. The period of increased risk was concentrated primarily within the 5-week period after vaccination, although it lasted for approximately 9 or 10 weeks.
ISSN:0002-9262
DOI:10.1093/oxfordjournals.aje.a112795